Medication 12: Alpha-Synuclein Inhibitors: Addressing Protein Aggregation
Alpha-synuclein inhibitors are a class of investigational drugs that target the accumulation of alpha-synuclein protein in the brain, a hallmark of Parkinson’s disease. By preventing the formation of toxic alpha-synuclein aggregates, these medications aim to slow the progression of neurodegeneration and alleviate Parkinson’s symptoms.
Several alpha-synuclein inhibitors are currently under investigation, including small molecules, monoclonal antibodies, and gene-silencing therapies. These approaches aim to reduce the production, aggregation, or toxicity of alpha-synuclein, thereby mitigating its detrimental effects on neurons.
While early results from clinical trials have shown promise, further research is needed to determine the safety and efficacy of alpha-synuclein inhibitors in Parkinson’s patients. Additionally, questions remain regarding the optimal timing of treatment and the potential for combination therapies with other Parkinson’s medications. (12)
